News

Organic revenue growth, which includes the adjustments noted in the attached reconciliation, was flat as against to the first quarter of 2008. Revenue from continuing operations in the

Umicore, a catalyst manufacturing company and Solvias, a technology provider have entered into a long term collaboration allowing quid pro quo access to each company’s respective asymmetric catalysis

Bayer, a producer of polymers and high-performance plastics, has reported a fall in the net income for the first quarter of 2009 by 44% to E425m compared to

Myriad Genetics, a developer of molecular diagnostic and therapeutic products, has launched OnDose, the company’s seventh molecular diagnostic product. According to Myriad Genetics, OnDose utilizes a technology to

For the first quarter of 2009, research and development expenses were $7.3, compared to $8.6 million for the same period in 2008. The decrease in research and development

The increase in net loss during the first quarter of 2009, against first quarter of 2008, reflects increased general and administrative expenses and expenses associated with the planned

Revenues of $26.3 million for the fourth quarter, down 1% over last year’s comparable quarter. Veterinary sales in North America of $16.5 million for the fourth quarter, up

Company Outlook IRIS International reaffirms initial guidance for full year 2009, anticipating revenue growth to at least $102 million and earnings of at least $0.48 per fully diluted

On a consolidated basis, first quarter net revenues grew 7.0% (13.8% excluding the impact of foreign exchange), operating margin was 12.7%, and diluted EPS of $0.63 met our